Poseida Therapeutics, Inc. (PSTX)
Jan 8, 2025 - PSTX was delisted (reason: acquired by Roche)
9.50
0.00 (0.00%)
Inactive · Last trade price on Jan 7, 2025

Poseida Therapeutics Revenue

Poseida Therapeutics had revenue of $71.75M in the quarter ending September 30, 2024, with 667.19% growth. This brings the company's revenue in the last twelve months to $150.86M, up 203.18% year-over-year. In the year 2023, Poseida Therapeutics had annual revenue of $64.70M, down -50.42%.

Revenue (ttm)
$150.86M
Revenue Growth
+203.18%
P/S Ratio
6.08
Revenue / Employee
$457,145
Employees
330
Market Cap
928.85M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202364.70M-65.79M-50.42%
Dec 31, 2022130.49M99.25M317.73%
Dec 31, 202131.24M--
Dec 31, 2020---
Dec 31, 2019---
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.